Is Verastem, Inc. (VSTM) a Buy, Sell, or Hold?
NASDAQ : VSTM
Verastem, Inc.
$6.79 USD
$0.05 (0.74%)
- Volume
- 2.29M
- Average Volume
- 2.47M
- Market Capitalization
- $596.66M
- P/E Ratio
- -2.76
- Dividend Yield
- 0.00%
- Price Target
- $13.50
- Year High
- $11.25
- Year Low
- $3.43
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $2.25
Company Overview
NASDAQ
Daniel W. Paterson
Biotechnology
Healthcare
VSTM
102
US
USD
Liquidity Metrics
1.69
2.25
2.22
1.75
0.00
Sales & Valuation
$30.91M
6.82
13.60
-3.65
-1.63
Profitability
-$3.02
-$209.47M
-231.59%
-230.65%
-467.49%
-98.15%
P/E Metrics
-2.76
-0.11
-0.11
Analyst Price Target & Rating
$13.50
$18.00
$8.00
1/5
19 Analysts
-49.70%
Financial Health Scores
-8.32
4/9
$98.02M
$206.51M
$156.52M
-$200.22M
Key Metrics (TTM)
$532.3M
6.08
-2.67
2.25
-467.49%
-123.02%
-30.04%
-27.61%
-367 days
Company Executives
| Name | Title |
|---|---|
| Daniel W. Paterson | President, Chief Executive Officer & Director |
| Julissa Viana | Vice President of Corporate Communications & Investor Relations |
| Daniel Calkins | Chief Financial Officer |
| Michelle Detwiler | Co-Founder |
| Jonathan Pachter | Chief Scientific Officer |
| Mark J. Wanda | Senior VP of Legal & Chief Compliance Officer |
| Lori Horvat | Executive Vice President of Portfolio Strategy & Operations |
| Robert A. Weinberg | Co-Founder & Chair of Scientific Advisory Board |
| Michael Glen Kauffman | President of Development & Director |
| Cathy Carew | Chief Organizational Effectiveness Officer |
Poll Results
No votes yet today — be the first to share your view!
About Verastem, Inc. (NASDAQ:VSTM) Stock
Verastem, Inc. is an emerging biopharmaceutical company dedicated to the creation and commercialization of innovative therapeutic agents for cancer treatment. A primary asset in its pipeline is VS-6766, a novel dual RAF/MEK inhibitor that operates by a "clamp" mechanism. This unique action effectively blocks the kinase activity of MEK and disrupts RAF's ability to phosphorylate MEK. The company is actively advancing several clinical trials. RAMP 201 is an adaptive, two-part, multicenter, randomized, open-label study designed to assess both the efficacy and safety of VS-6766, administered alone or in combination with defactinib. Defactinib is an oral small molecule inhibitor of focal adhesion kinase (FAK), and this trial targets patients with recurrent low-grade serous ovarian cancer. Simul ... taneously, Verastem is conducting RAMP 202, a Phase 2 trial focused on evaluating the safety profile of VS-6766 combined with defactinib. This particular study enrolls patients with non-small cell lung cancer (NSCLC) that harbors KRAS and BRAF mutations, specifically after they have undergone treatment with platinum-based regimens and immune checkpoint inhibitors. Verastem has also forged strategic partnerships to support its development efforts. It holds license agreements with Chugai Pharmaceutical Co., Ltd. for the development, commercialization, and manufacturing rights of products incorporating VS-6766. Additionally, a similar agreement with Pfizer Inc. pertains to the research, development, production, and marketing of Pfizer's FAK inhibitors for various human applications, including therapeutic, diagnostic, and prophylactic uses. Further expanding its collaborations, Verastem has a clinical agreement with Amgen, Inc. to explore the synergistic potential of VS-6766 alongside Amgen's KRAS-G12C inhibitor, LUMAKRAS™, a combination being investigated in the Phase 1/2 RAMP 203 trial. Founded in 2010, Verastem, Inc. maintains its corporate headquarters in Needham, Massachusetts.
Verastem Q2 Earnings Call Highlights
2026-08-07 16:05:46
Verastem NASDAQ: VSTM reported second-quarter 2026 net product revenue of $25.1 million from sales of its AVMAPKI FAKZYNJA CO-PACK, as the company said increased new patient starts, refills and physician adoption supported a rebound in commercial performance.
Verastem, Inc. (VSTM) Q2 2026 Earnings Call Transcript
2026-08-07 12:34:27
Verastem, Inc. (VSTM) Q2 2026 Earnings Call Transcript
Verastem (VSTM) Reports Q2 Loss, Beats Revenue Estimates
2026-08-06 18:40:48
Verastem (VSTM) came out with a quarterly loss of $0.35 per share versus the Zacks Consensus Estimate of a loss of $0.46. This compares to a loss of $0.39 per share a year ago.
2026-08-06 16:01:00
BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today reported financial results for the second quarter ended June 30, 2026, and highlighted recent business progress. “The second quarter marked meaningful progress across our commercial business and pipeline programs, with strong quarter-over-quarter growth for AVMAPKI FAKZYNJA CO-PACK driven by new patient starts and in.
2026-07-28 16:01:00
BOSTON--(BUSINESS WIRE)---- $VSTM #CRC--Verastem doses first patient in TARGET-D 203, a registration-directed Phase 2 trial of VS-7375 in KRAS G12D-mutated metastatic colorectal cancer.
Verastem Oncology to Report Second Quarter 2026 Financial Results on August 6, 2026
2026-07-23 07:30:00
BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced that the Company will host a conference call and webcast to discuss its second quarter 2026 financial results and business updates on Thursday, August 6, 2026, at 4:30 pm ET. A live audio webcast of the call, along with accompanying slides, will be available under "Events & Presentations" in the Investo.
2026-07-22 16:01:00
BOSTON--(BUSINESS WIRE)---- $VSTM #CRC--Verastem doses first patient in TARGET-D 202, a registration-directed Phase 2 clinical trial of VS-7375 in KRAS G12D-mutated advanced NSCLC.
Verastem (VSTM) Surges 6.3%: Is This an Indication of Further Gains?
2026-07-10 06:46:05
Verastem (VSTM) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Frequently Asked Questions
-
What is the current Verastem, Inc. (VSTM) stock price?
-
Verastem, Inc.(NASDAQ:VSTM) stock price is $6.79 in the last trading session. During the trading session, VSTM stock reached the peak price of $11.25 while $3.43 was the lowest point it dropped to. The percentage change in VSTM stock occurred in the recent session was 0.74% while the dollar amount for the price change in VSTM stock was $0.05.
-
VSTM's industry and sector of operation?
-
The NASDAQ listed VSTM is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of VSTM?
-
Daniel W. Paterson | President, Chief Executive Officer & Director
Julissa Viana | Vice President of Corporate Communications & Investor Relations
Daniel Calkins | Chief Financial Officer
Michelle Detwiler | Co-Founder
Jonathan Pachter | Chief Scientific Officer -
How many employees does VSTM have?
-
Number of VSTM employees currently stands at 102. VSTM operates from 117 Kendrick Street, Needham, MA 02494, US.
-
Link for VSTM official website?
-
Official Website of VSTM is: https://www.verastem.com
-
How do I contact VSTM?
-
VSTM could be contacted at phone #781 292 4200 and can also be accessed through its website. VSTM operates from 117 Kendrick Street, Needham, MA 02494, US.
-
How many shares of VSTM are traded daily?
-
The average number of VSTM shares traded daily for last 3 months was 2.47M.
-
What is the market cap of VSTM currently?
-
The market value of VSTM currently stands at $596.66M with its latest stock price at $6.79